Enterprise Europe Network (TRKR20180723001)

Short description of advertisement: 
Pharmaceutical compositions that act as adenosine receptor antagonist which cures liver diseases, such as Nonalcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis of liver containing adenosine derivatives

A bio-venture Korean SME has developed first-in-class drug synthesis since established in 2015, and the company represents new drug candidates that have an efficiency of relief on Nonalcoholic Steatohepatitis, Liver Fibrosis, and Liver Cirrhosis, which are called Adenosine Receptor Antagonist. The company came up with the idea due to lack of pharmaceutical treatment for NASH. The company is, thus, open to take the partnership of license and commercial agreement with technical assistant.

A Korean company established in 2015 is based on research of pharmaceutical products and drugs. 

Nonalcoholic fatty liver disease (NAFLD) is caused by obesity and diabetes, and it includes simple steatosis, Nonalcoholic Steatohepatitis (NASH) along with liver cell disruption, inflammation, and fibrosis, and Cirrhosis of liver. 

There is approximately 20~30% of population suffering from NAFLD due to geriatric diseases, and NASH is caused approximately 10~20% of NAFLD patients, and 9~25% of them suffers from liver cirrhosis and liver cancer eventually.
Not all of patients has NASH, however in case of causing it, it results in death due to complication. Therefore, there is point that stage of NASH has to be cured for NAFLD.

The existing new drug candidate materials have 72% and 85% of sequence homology to human’s receptors in case of rat and sheep respectively, which shows a low rate of receptors. In spite of excellent results of animal test on new drug materials, it could not be examined the same result on clinical trial. However, the company examined the equal binding affinity with human regardless of species. 

The company is looking for partners who would solve the problems on the existing materials and develop new treatment for non-alcoholic steatohepatitis and make them sued in pharmaceutical industry under commercial agreement with technical assistance and license agreement.



For more information please contact Enterprise Europe Network Latvia.

Contact person: 
Enterprise Europe Network Latvia
Contact languages: 
South Korea
Perses iela 2, Riga, LV-1442, Latvia
info [at] een [dot] lv
Valid till: 
Monday, 25 November, 2019